These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-003839-31 A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab in Crohn's Disease Subjects Who Have Previously Participated in Natalizumab Crohn's Disease Study C... bad-data
Not reported 2004-004120-12 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Amyloid-Imaging Positron Emission Tomography (PET) Trial of AAB-001 (ELN115727) in Patie... 2009-11-12 due-trials
Not reported Terminated 2006-004675-35 A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability and Efficacy of AAB-001 (ELN115727) in Patients with Alzheimer's Disease who Participated in Study ... 2009-05-14 due-trials
Reported results 2012-001935-30 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder 2014-06-09 due-trials
Reported results 2012-004299-20 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's... 2015-05-12 due-trials
Reported results 2012-005524-15 A 12-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease. Estudio de extensión de 12 semanas para evaluar l... 2015-08-18 due-trials

Related organisations

Over time organisations can merge, or split.

We think Elan Pharma International Ltd is now effectively part of Perrigo.